MolDX: Breast Cancer Index® (BCI) Gene Expression Test

The BCI gene expression test is covered on a limited basis for postmenopausal women with invasive ER+ and/or PR+ and HER2- early-stage (T1-T3, pN0-pN1, M0) breast cancer when there is no distant metastasis and results will be used to guide chemotherapy and/or endocrine therapy decisions. Required documentation includes pathology with receptor status, TNM staging, confirmation of postmenopausal status, and clinical justification that the test will inform treatment management.

"BCI is covered to provide a genomic-based estimate of distant recurrence risk to inform the decision about adding adjuvant chemotherapy."

Sign up to see full coverage criteria, indications, and limitations.